Aberrant AKT/mTOR signaling is a hallmark observed in many cancertypes, including colon cancer, angiosarcoma, and breast cancer.51−53 The synergistic interplay between HDACi and AKT/mTOR signaling hasalso been proposed as a potential mechanism of action behind the anticancereffects of HDACi in a variety of cancer models (reviewed in refs (54) and (55)). This evidence concerns the gene MTOR and breast carcinoma.